CXCR6 and neoplasm: We observed a significant increase in the frequency of the effector like CXCR6+CD44+ cluster in the tumor from Arid2-deleted CD8+ T cell recipients compared with the control (26.2% versus 8.72%) (Figures 7H and 7I).